bioMérieux
A global leader in in vitro diagnostics for clinical and industrial applications.
BIM | PA
Overview
Corporate Details
- ISIN(s):
- FR0013280286 (+13 more)
- LEI:
- 549300AK8Y0LBIQ4T071
- Country:
- France
- Address:
- 376 CHE DE L'ORME, 69280 MARCY-L'ETOILE
- Website:
- https://www.biomerieux.com/
- Sector:
- Manufacturing
Description
bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-10-08 10:40 |
Septembre 2024 - Déclaration sur le nombre d'actions composant le capital socia…
|
French | PDF • 105.3 KB | ||
| 2024-09-05 12:00 |
Rapport Financier Semestriel 2024
|
French | PDF • 2.2 MB | ||
| 2024-09-05 07:01 |
bioMérieux – First-Half 2024 Results
|
English | PDF • 528.8 KB | ||
| 2024-09-05 07:01 |
bioMérieux – Résultats semestriels au 30 juin 2024
|
French | PDF • 420.8 KB | ||
| 2024-08-06 17:34 |
Juillet 2024 Déclaration sur le nombre d'actions composant le capital social e…
|
French | PDF • 85.3 KB | ||
| 2024-07-05 15:52 |
Juin 2024 - Déclaration sur le nombre d'actions composant le capital social et …
|
French | PDF • 106.1 KB | ||
| 2024-06-26 07:01 |
bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its B…
|
English | PDF • 230.2 KB | ||
| 2024-06-26 07:01 |
bioMérieux obtient l’autorisation spéciale 510(k) et la dérogation CLIA pour so…
|
French | PDF • 235.6 KB | ||
| 2024-06-21 08:35 |
bioMérieux receives US FDA 510(k) clearance for its AST System VITEK® REVEAL™
|
English | PDF • 244.0 KB | ||
| 2024-06-21 08:35 |
bioMérieux obtient l’autorisation 510(k) de la FDA américaine pour son système …
|
French | PDF • 245.2 KB | ||
| 2024-06-05 11:22 |
Mai 2024 - Déclaration sur le nombre d'actions composant le capital social et s…
|
French | PDF • 106.1 KB | ||
| 2024-05-28 18:01 |
bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innov…
|
English | PDF • 273.5 KB | ||
| 2024-05-28 18:01 |
bioMérieux obtient l'agrément 510(k) de la FDA pour le test innovant VIDAS® TBI…
|
French | PDF • 279.4 KB | ||
| 2024-05-23 13:02 |
Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisec…
|
English | PDF • 243.7 KB | ||
| 2024-05-23 13:02 |
Le Ministère de la Santé du Malawi, bioMérieux et Pfizer créent la première col…
|
French | PDF • 235.0 KB |
Automate Your Workflow. Get a real-time feed of all bioMérieux filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for bioMérieux
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for bioMérieux via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-04 | N/A | Other | Sell | 1,432 | 137,517.82 EUR |
| 2023-09-04 | N/A | Other | Sell | 1,253 | 120,328.10 EUR |
| 2023-09-01 | N/A | Other | Other | 2,900 | N/A |
| 2023-06-23 | N/A | Other | Other | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 300 | 23,193.00 EUR |
| 2023-06-23 | N/A | Other | Buy | 25 | 1,932.75 EUR |
| 2023-03-23 | N/A | Other | Sell | 16,500 | 1,650,415.80 EUR |
Peer Companies
